| Welslau, Manfred |
NeoON, NCT05036005: Neoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label |
|
|
| Recruiting | 4 | 108 | Europe | Ontruzant, SB3, Chemotherapy, Pertuzumab | Institut fuer Frauengesundheit, Samsung Bioepis Co., Ltd. | Breast Cancer, Breast Neoplasms, Breast Cancer Female, HER2-positive Breast Cancer | 04/23 | 07/23 | | |
CAPTOR-BC, NCT05452213: Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients |
|
|
| Recruiting | 4 | 1000 | Europe | Ribociclib | Institut fuer Frauengesundheit, AGO Breast Study Group e.V., Novartis Pharmaceuticals | Breast Cancer, Breast Neoplasms, Breast Neoplasm Female, Breast Cancer Female, HER2-negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Advanced Breast Cancer | 10/24 | 10/26 | | |
NCT03897127: Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagnosed AML and Intermediate- or Adverse Genetics |
|
|
| Recruiting | 3 | 882 | Europe | Cytarabine, Daunorubicin, CPX-351 | University of Ulm, Jazz Pharmaceuticals | Acute Myeloid Leukemia | 06/27 | 06/27 | | |
HOVON 156 AML, NCT04027309 / 2018-000624-33: A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy |
|
|
| Active, not recruiting | 3 | 777 | Europe, RoW | Gilteritinib, ASP2215, Midostaurin, Rydapt | Stichting Hemato-Oncologie voor Volwassenen Nederland, Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG), Astellas Pharma Global Development, Inc. | Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2 | 12/24 | 06/33 | | |
ARASAFE, NCT05676203: A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + ADT in mHSPC Patients |
|
|
| Recruiting | 3 | 250 | Europe | Standard ADT (androgen deprivation therapy), Standard Darolutamide, Docetaxel | Jena University Hospital, Bayer | Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | 02/25 | 08/26 | | |
ARCHED, NCT05820841: Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma |
|
|
| Recruiting | 3 | 330 | Europe | R-miniCHOP + Acalabrutinib, R-miniCHOP | Universität des Saarlandes, University of Leipzig, University Hospital Regensburg, Wuerzburg University Hospital, University Hospital of Gießen and Marburg, Saarland University Medical Center, AstraZeneca | Large B-cell Lymphoma, Diffuse Large B Cell Lymphoma | 04/28 | 12/28 | | |
NCT02131753: Therapy Optimisation for the Treatment of Hairy Cell Leukemia |
|
|
| Recruiting | 2/3 | 210 | Europe | Cladribine s.c. injection, HCL treatment, Litak(R), 2-CdA | University of Giessen | Hairy Cell Leukemia | 12/25 | 12/27 | | |
NCT03530267: Aflibercept and 5-FU vs. FOLFOX as 1st Line Treatment for Elderly or Frail Elderly Patients With Met. Colorectal Cancer |
|
|
| Completed | 2 | 124 | Europe | Aflibercept + mLV5FU2, mFOLFOX7 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, STABIL - Statistische und Biometrische Lösungen, Trium Analysis Online GmbH, Sanofi | Colorectal Cancer | 02/24 | 02/24 | | |
AMLSG BiO, NCT01252485: Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms - the Biology and Outcome (BiO)-Project |
|
|
| Recruiting | N/A | 50000 | Europe | | University of Ulm | Acute Myeloid Leukemia (AML), MDS/AML | 12/44 | 12/44 | | |
INFINITY, NCT04389541: Clinical Research Platform on Decision Making and Clinical Impact of Biomarker-Driven Precision Oncology |
|
|
| Completed | N/A | 499 | Europe | | iOMEDICO AG, Bristol-Myers Squibb, Roche Pharma AG | Advanced Solid Tumors or Hematologic Malignancies | 06/23 | 06/23 | | |
| Recruiting | N/A | 500 | Europe, RoW | Data collection and quality of life questionnaire | Centre Leon Berard | Cancer, Cancer Metastatic, NTRK Gene Fusion Overexpression, NTRK Family Gene Mutation, ATIC-ALK Fusion Protein Expression, ALK Fusion Protein Expression, BCR-FGFR1 Fusion Protein Expression, ROS1 Gene Translocation, COL1A1-PDGFB Fusion Protein Expression, RET Gene Translocation, Gene Fusion, ROS Gene Translocation, BRAF Gene Rearrangement, FGFR2 Gene Translocation, FGFR3 Gene Translocation, NTRK1 Gene Translocation | 06/25 | 06/25 | | |
| Recruiting | N/A | 1100 | Europe | | Jena University Hospital, University Hospital Dresden, Novartis, Swedish Orphan Biovitrum, Grifols Biologicals, LLC, Amgen, argenx | Immune Thrombocytopenia | 09/26 | 04/27 | | |
